How to use Technologies offered

A search for a cancer, preclinical stage, synthetic opportunity would use the selection "Therapeutics, Diagnostics" in 'Sector', 'Cancerous, neoplasmatic' in 'Disease Category', 'Drugs, Small Molecule' in 'Technology' and 'Preclinical' in 'Development Stage'.

Selection of 'Enabling Technology, Platform Technology' in 'Sector' will identify all kinds of research technologies that can be used in more areas of life sciences than pharmaceuticals only.

Each technology profile gives the name of a company or academic institute as source of the offer, and a link allowing to contact the potential licensor. In most cases a profile includes a pdf covering the available non-confidential information as well as detailed contact data.

Registered users can create non-public notifications profiles which will inform them about new 'Technologies Offered' entries fitting their needs as specified. In addition these profiles allow them to filter the available information more comfortably.

Name

Cartilage-specific antimicrobial CLEC3A

Organization name

PROvendis GmbH

Profile

Bacterial infection is one of the most frequent complications in joint replacement surgery. The incidence of septic arthritis following total joint arthroplasty is approximately 2%, leading to massive health problems and considerable cost to the national economy. A new approach to reduce such infections is made by coating prostheses and implants with bioactive, anti-infectious substances. In this context, coating with antimicrobial peptides has already been tested (see Gallo et al.), too, but a major drawback is the fact that such peptides from exogenous sources may cause an immune response.

Researchers of the Medical Faculty of the University of Cologne have now demonstrated that peptides of the cartilage-specific CLEC3A have antimicrobial activity against some of the most common nosocomial bacteria. Most strikingly, both Gram-negative and Gram-positive bacteria were killed by such fragments (please see figure). The clear advantage of these cartilage-specific CLEC3A-derived peptides is the lack of immunogenicity.

Commercial Opportunities

The invention is offered for licensing and further co development in collaboration with the researchers.

Competitive Advantages

  • Non-imunogenic peptide due to its natural expression in cartilage
  • Antibiotic activity against both Gram-positive and Gram-negative nosocomial bacteria
  • Suitable for surface coating of protheses

Current Status                                                                                                       

Several CLEC3A-derived peptides have been investigated to show antimicrobial activity. In addition, coating titanium substrates with CLEC3A-derived peptides significantly reduces bacterial adhesion on the titanium substrates.  Furthermore, it has been proven by the researchers that these peptides have no cytotoxicity against primary human chondrocytes.

In case of interest we will be pleased to inform you about the patent status.

Relevant Publication

Gallo, J., et al. (2014) Antibacterial surface treatment for orthopaedic implants. Int. J. Mol. Sci. 15: 13849-13880.

To view the contact information, attachments and url of this profile you have to login into your account or register a new account: Login Register

Your feedback

Please click here to log in to view the complete profile.

 
 

latest entries